Document:

Document

Exhibit 10(e)

EXECUTIVE RETENTION EMPLOYMENT AGREEMENT

Executive Retention Employment Agreement between NextEra Energy, Inc., a Florida corporation (the "Company"), and Robert P. Coffey (the "Executive"), dated as of June 14, 2021.  The Board of Directors of the Company (the "Board") has determined that it is in the best interests of the Company and its shareholders to assure that the Company and its Affiliated Companies will have the continued dedication of the Executive, notwithstanding the possibility, threat or occurrence of a Potential Change of Control or a Change of Control (each as defined below) of the Company. The Board believes it is imperative to diminish the inevitable distraction of the Executive by virtue of the personal uncertainties and risks created by the circumstances surrounding a Potential Change of Control or a Change of Control and to encourage the Executive's full attention and dedication to the Company and its Affiliated Companies currently and in the event of any Potential Change of Control or Change of Control (and, under certain circumstances, in the event of the termination or abandonment of a Change of Control transaction), and to provide the Executive with compensation and benefits arrangements which ensure that the compensation and benefits expectations of the Executive will be satisfied and which are competitive with those of other corporations which may compete with the Company for the services of the Executive. Therefore, in order to accomplish these objectives, the Board has caused the Company to enter into this Executive Retention Employment Agreement (this "Agreement").

Therefore, the Company and the Executive agree as follows:

1.Effective Date; Term.
(a) Effective Date.  The effective date of this Agreement (the "Effective Date") shall be the date on which (i) a Potential Change of Control occurs, (ii) the Company’s shareholders approve a plan of complete liquidation or dissolution of the Company, (iii) a Change of Control occurs pursuant to Section 2(a)(1) or (2) below, or (iv) a definitive agreement is signed by the Company which provides for a transaction that, if approved by shareholders or consummated, as applicable, would result in a Change of Control pursuant to Section 2(a)(3) or (4) below; provided, however, that any of the foregoing which may have occurred prior to the date hereof shall be disregarded. Anything in this Agreement to the contrary notwithstanding, if, prior to the Effective Date, the Executive's employment with the Company or its Affiliated Companies was terminated by the Company or its Affiliated Companies, or both, as applicable, other than for Cause or Disability (each as defined below) or by the Executive for Good Reason (as defined below) and the Executive can reasonably demonstrate that such termination (or the event constituting Good Reason) took place (a) at the request or direction of a third party who took action that caused a Potential Change of Control or (b) in contemplation of an event that would give rise to an Effective Date, an Effective Date will be deemed to have occurred (“Deemed Effective Date”) immediately prior to the Date of Termination (as defined in Section 6(e) below), provided that a Change of Control occurs within a six-month period following such Date of Termination. As used in this Agreement, the term "Affiliated Companies" shall include any corporation or other entity controlled by, controlling or under common control with the Company and the term “Subsidiary” shall mean (x) any corporation or other entity (other than the Company) with respect to which the Company owns, directly or indirectly, 50% or more of the total combined voting power of all classes of stock or other ownership interests or (y) any other related entity which may be designated by the Board as a Subsidiary, provided such entity could be considered a subsidiary according to generally accepted accounting principles.

1

(b) Term.  The term of this Agreement shall commence on June 14, 2021 and end on June 14, 2024 (“Initial Term”). However, at the end of the Initial Term, and, if extended, at the end of each additional year thereafter, so long as the Executive is still an employee of the Company, the term of this Agreement will be automatically extended for another year, unless the Company shall have provided written notice to the Executive at least six months before the end of the then-current term that it does not want the term to be extended. Notwithstanding the foregoing, this Agreement shall not terminate during the Employment Period.

2.Change of Control; Potential Change of Control.
For the purposes of this Agreement:

(a)A "Change of Control" shall mean the first (and only the first) to occur of the following:

(1)The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (x) the then outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (y) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that the following acquisitions (collectively, the "Excluded Acquisitions") shall not constitute a Change of Control (it being understood that shares acquired in an Excluded Acquisition may nevertheless be considered in determining whether any subsequent acquisition by such individual, entity or group (other than an Excluded Acquisition) constitutes a Change of Control): (i) any acquisition directly from the Company or any Subsidiary; (ii) any acquisition by the Company or any Subsidiary; (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary; (iv) any acquisition by an underwriter temporarily holding Company securities pursuant to an offering of such securities; (v) any acquisition in connection with which, pursuant to Rule 13d-1 promulgated pursuant to the Exchange Act, the individual, entity or group is permitted to, and actually does, report its beneficial ownership on Schedule 13G (or any successor Schedule); provided that, if any such individual, entity or group subsequently becomes required to or does report its beneficial ownership on Schedule 13D (or any successor Schedule), then, for purposes of this paragraph, such individual, entity or group shall be deemed to have first acquired, on the first date on which such individual, entity or group becomes required to or does so report, beneficial ownership of all of the Outstanding Company Common Stock and/or Outstanding Company Voting Securities beneficially owned by it on such date; or (vi) any acquisition in connection with a Business Combination (as hereinafter defined) which, pursuant to subparagraph (3) below, does not constitute a Change of Control; or

(2)Individuals who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest with respect to the election or 

2

removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of an individual, entity or group other than the Board; or
(3)Consummation by the Company of a reorganization, merger, consolidation or other business combination (any of the foregoing, a "Business Combination") of the Company or any Subsidiary of the Company with any other corporation, in any case with respect to which:

(i)the Outstanding Company Voting Securities outstanding immediately prior to such Business Combination do not, immediately following such Business Combination, continue to represent (either by remaining outstanding or being converted into voting securities of the resulting or surviving entity or any ultimate parent thereof) more than 55% of the outstanding common stock and of the then outstanding voting securities entitled to vote generally in the election of directors of the resulting or surviving entity (or any ultimate parent thereof); or

(ii)less than a majority of the members of the board of directors of the resulting or surviving entity (or any ultimate parent thereof) in such Business Combination (the "New Board") consists of individuals ("Continuing Directors") who were members of the Incumbent Board (as defined in subparagraph (2) above) immediately prior to consummation of such Business Combination (excluding from Continuing Directors for this purpose, however, any individual whose election or appointment to the Board was at the request, directly or indirectly, of the entity which entered into the definitive agreement with the Company or any Subsidiary providing for such Business Combination); or

(4)(i) Consummation of a sale or other disposition of all or substantially all of the assets of the Company, other than to a corporation with respect to which, following such sale or other disposition, more than 55% of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the Outstanding Company Common Stock and Outstanding Company Voting Securities as the case may be; or (ii) shareholder approval of a complete liquidation or dissolution of the Company.

The term "the sale or disposition by the Company of all or substantially all of the assets of the Company" shall mean a sale or other disposition transaction or series of related transactions involving assets of the Company or of any Subsidiary (including the stock of any Subsidiary) in which the value of the assets or stock being sold or otherwise disposed of (as measured by the purchase price being paid therefor or by such other method as the Board determines is appropriate in a case where there is no readily ascertainable purchase price) constitutes more than two-thirds of the fair market value of the Company (as hereinafter defined). The "fair market value of the Company" shall be the aggregate market value of the then Outstanding Company Common Stock (on a fully diluted basis) plus the aggregate market value of the Company's other outstanding equity securities. The aggregate market 

3

value of the shares of Outstanding Company Common Stock shall be determined by multiplying the number of shares of Outstanding Company Common Stock (on a fully diluted basis) outstanding on the date of the execution and delivery of a definitive agreement with respect to the transaction or series of related transactions (the "Transaction Date") by the average closing price of the shares of Outstanding Company Common Stock for the ten trading days immediately preceding the Transaction Date. The aggregate market value of any other equity securities of the Company shall be determined in a manner similar to that prescribed in the immediately preceding sentence for determining the aggregate market value of the shares of Outstanding Company Common Stock or by such other method as the Board shall determine is appropriate.

(b)A "Potential Change of Control" shall be deemed to have occurred if an event set forth in either of the following subparagraphs shall have occurred:

(1)the Company or any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act)publicly announces or otherwise communicates to the Board in writing an intention to take or to consider taking actions (e.g., a "bear hug" letter, an unsolicited offer or the commencement of a proxy contest) which, if consummated or approved by shareholders, as applicable, would constitute a Change of Control; or

(2)any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) directly or indirectly, acquires beneficial ownership of 15% or more of the Outstanding Company Common Stock or Outstanding Company Voting Securities; provided, however, that Excluded Acquisitions shall not constitute a Potential Change of Control.

3.Employment Period.
(a)The Company hereby agrees to continue the Executive in its or its Affiliated Companies' employ, or both, as the case may be, and the Executive hereby agrees to remain in the employ of the Company, or its Affiliated Companies, or both, as the case may be, subject to the terms of this Agreement, for a period commencing on the Effective Date and ending on the second anniversary of the Effective Date (such period or, if shorter, the period from the Effective Date to the Date of Termination, is hereinafter referred to as the "Employment Period").

(b)Anything in this Agreement to the contrary notwithstanding, (x) if an Effective Date occurs (other than as a result of a Change of Control under Section 2(a)(1) or (2) above) and the Board adopts a resolution to the effect that the event or circumstance giving rise to the Effective Date no longer exists (including by reason of the termination or abandonment of the transaction contemplated by the definitive agreement referred to in clause (iv) of Section 1 hereof), the Employment Period shall terminate on the date the Board adopts such resolution, but this Agreement shall otherwise remain in effect, and (y) if a Change of Control occurs pursuant to Section 2(a)(3) or (4) above during the Employment Period, the Employment Period shall immediately extend to and end on the second anniversary of the date of such Change of Control (or, if earlier, to the Date of Termination) and a new Effective Date will be deemed to have occurred on the date of such Change of Control.
4.Position and Duties.

4

During the Employment Period, the Executive's titles and reporting requirements with the Company or its Affiliated Companies or both, as the case may be, shall be commensurate with those in effect during the 90-day period immediately preceding the Effective Date. The duties and responsibilities assigned to the Executive may be increased, decreased or otherwise changed during the Employment Period, provided that the duties and responsibilities assigned to the Executive at any given time are not a material diminution of the Executive's titles and reporting requirements as in effect during the 90-day period immediately preceding the Effective Date. The Executive's services shall be performed at the location where the Executive was employed immediately preceding the Effective Date or any location less than 50 miles from such location, although the Executive understands and agrees that he may be required to travel from time to time for business purposes.

During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to devote substantially all of his time and attention during normal business hours to the business and affairs of the Company and its Affiliated Companies and to use his reasonable best efforts to perform faithfully and efficiently the duties and responsibilities assigned to him hereunder.  During the Employment Period it shall not be a violation of this Agreement for the Executive to serve on corporate, civic or charitable boards or committees, deliver lectures, fulfill speaking engagements or teach at educational institutions and devote reasonable amounts of time to the management of his and his family's personal investments and affairs, so long as such activities do not significantly interfere with the performance of the Executive's responsibilities as an employee of the Company or its Affiliated Companies in accordance with this Agreement. It is expressly understood and agreed that to the extent that any such activities have been conducted by the Executive prior to the Effective Date, the reinstatement or continued conduct of such activities (or the reinstatement or conduct of activities similar in nature and scope thereto) subsequent to the Effective Date shall not thereafter be deemed to interfere with the performance of the Executive's responsibilities to the Company and its Affiliated Companies.

5.Compensation.
During the Employment Period, the Executive shall be compensated as follows:

(a)Annual Base Salary. The Executive shall be paid an annual base salary ("Annual Base Salary"), in equal biweekly installments or otherwise in accordance with the Company’s then-current payroll practice, at least equal to the annual rate of base salary being paid to the Executive by the Company and its Affiliated Companies as of the Effective Date. The Annual Base Salary shall be reviewed at least annually and shall be increased substantially consistent with increases in base salary generally awarded to other peer executives of the Company and its Affiliated Companies.  Any increase in Annual Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement. Annual Base Salary shall not be reduced after any such increase and the term "Annual Base Salary" as utilized in this Agreement shall refer to Annual Base Salary as so increased.

(b)Annual Bonus. In addition to Annual Base Salary, upon the terms and subject to the conditions of this paragraph (b), the Executive shall, for each fiscal year ending during the Employment Period, be entitled to an annual cash bonus (the "Annual Bonus") opportunity equal to a percentage of his Annual Base Salary. Such percentage shall be substantially consistent with the 

5

targeted percentages generally awarded to other peer executives of the Company and its Affiliated Companies, but at least equal to the higher of (i) the percentage obtained by dividing his targeted annual bonus for the then current fiscal year by his then Annual Base Salary or (ii) the average percentage of his annual base salary (as in effect for the applicable years) that was paid or payable, including by reason of any deferral, to the Executive by the Company and its Affiliated Companies as an annual bonus (however described, including as annual incentive compensation) for each of the three fiscal years immediately preceding the fiscal year in which the Effective Date occurs (or, if higher, for each of the three fiscal years immediately preceding the fiscal year in which a Change of Control occurs, if a Change of Control occurs following the Effective Date). For the purposes of any calculation required to be made under clause (ii) of the preceding sentence, an annual bonus shall be annualized for any fiscal year consisting of less than twelve full months or with respect to which the Executive was employed for, and received pro-rated annual incentive compensation with respect to, less than the full twelve months, and, if the Executive has not been employed for the full duration of the three fiscal years immediately preceding the year in which the Effective Date occurs, the average shall be calculated over the duration of the Executive's employment in such period. Each such Annual Bonus shall be paid no later than the end of the second month of the fiscal year next following the fiscal year for which the Annual Bonus is awarded, unless the Executive otherwise elects to defer the receipt of such Annual Bonus in accordance with a deferred compensation plan of the Company or its Affiliated Companies that complies with Section 409A of the Internal Revenue Code (the “Code”). The foregoing provisions of this paragraph (b) shall be qualified by the following terms and conditions. 

(c)Long Term Incentive Compensation. During the Employment Period, the Executive shall be entitled to participate in all incentive compensation plans, practices, policies, and programs applicable generally to other peer executives of the Company and its Affiliated Companies, but in no event shall such plans, practices, policies, and programs provide the Executive with incentive opportunities and potential benefits, both as to amount and percentage of compensation, less favorable, in the aggregate, than those provided by the Company and its Affiliated Companies for the Executive under the NextEra Energy, Inc. Amended and Restated 2011 Long Term Incentive Plan (or its successor) (including, without limitation, performance share awards, stock option grants and restricted stock awards), or other plan providing for the grant of equity compensation for executive officers, as in effect at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its Affiliated Companies.

(d)Savings and Retirement Plans. During the Employment Period, the Executive shall be entitled to participate in all savings and retirement plans (whether tax-qualified or non-qualified plans), practices, policies, and programs applicable generally to other peer executives of the Company and its Affiliated Companies, but in no event shall such plans, practices, policies, and programs provide the Executive with savings opportunities and retirement benefit opportunities, in each case, less favorable, in the aggregate, than the most favorable of those provided by the Company and its Affiliated Companies for the Executive under such plans, practices, policies, and programs as in effect at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its Affiliated Companies.

6

(e)Benefit Plans. During the Employment Period, the Executive and/or the Executive's family, as the case may be, shall be eligible for participation in and shall receive all benefits under welfare benefit plans, practices, policies, and programs provided by the Company and its Affiliated Companies (including, without limitation, medical, executive medical, annual executive physical, prescription, dental, vision, short-term disability, long-term disability, executive long-term disability, salary continuance, employee life, group life, accidental death and dismemberment, and travel accident insurance plans and programs) to the extent applicable generally to other peer executives of the Company and its Affiliated Companies, but in no event shall such plans, practices, policies, and programs provide the Executive with benefits which are less favorable, in the aggregate, than the most favorable of such plans, practices, policies, and programs in effect for the Executive at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its Affiliated Companies.

(f)Expenses. During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive in accordance with the most favorable policies, practices, and procedures of the Company and its Affiliated Companies in effect for the Executive at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its Affiliated Companies. The payment of such reimbursements shall be made within thirty (30) days after submission of requests for reimbursement in accordance with applicable policies and procedures of the Company. Notwithstanding anything to the contrary in this Section 5(f) or elsewhere, reimbursement of expenses will be made consistent with the Company’s Expense Reimbursement Policy, which is intended to comply with the requirements of Code
Section 409A and Treasury Regulation Section 1.409A-3(i)(1)(iv).

(g)Fringe Benefits. During the Employment Period, the Executive shall be entitled to fringe benefits in accordance with the most favorable plans, practices, programs, and policies of the Company and its Affiliated Companies in effect for the Executive at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its Affiliated Companies.

(h)Vacation. During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the most favorable plans, policies, programs, and practices of the Company and its Affiliated Companies as in effect for the Executive at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its Affiliated Companies.  In addition to, and notwithstanding anything to the contrary in the preceding sentence, any unused vacation days shall be carried over from year to year in accordance with Company policy as in effect immediately prior to the commencement of the Employment Period. 

6.Termination of Employment.

7

(a)Death or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the Employment Period. If the Company determines in good faith that the Disability of the Executive has occurred during the Employment Period (pursuant to the definition of Disability set forth below), it may give to the Executive written notice in accordance with Section 14(b) of this Agreement of its intention to terminate the Executive's employment. In such event, the Executive's employment with the Company shall terminate effective on the 30th day after receipt of such notice by the Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, the Executive shall not have returned to full-time performance of the Executive’s duties. For purposes of this Agreement, "Disability" shall mean the absence of the Executive from the Executive's duties with the Company on a full-time basis for 180 consecutive business days as a result of incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive's legal representative (such agreement as to acceptability not to be withheld unreasonably).

8

(b)Cause. The Company may terminate the Executive's employment during the Employment Period for Cause. For purposes of this Agreement, "Cause" shall mean (i) repeated violations by the Executive of the Executive's obligations under Section 4 of this Agreement (other than as a result of incapacity due to physical or mental illness) which are demonstrably willful and deliberate on the Executive's part, which are committed in bad faith or without reasonable belief that such violations are in the best interests of the Company and which are not remedied in a reasonable period of time after receipt of written notice from the Company specifying such violations (ii) material violation of the Company’s Code of Business Conduct & Ethics; (iii) intentional misconduct that results in financial or reputational harm to the Company or its Affiliated Companies; (iv) violation of the Protective Covenants set forth in Section 11 below; or (v) the conviction of the Executive of a felony involving an act of dishonesty intended to result in substantial personal enrichment at the expense of the Company or its Affiliated Companies.

(c)Good Reason. The Executive's employment may be terminated during the Employment Period by the Executive for Good Reason. For purposes of this Agreement, "Good Reason" shall mean:

(1)any failure by the Company to comply with the provisions of Section 4 of this Agreement, including without limitation, the assignment to the Executive of any duties and responsibilities that are a material diminution of the Executive's duties and responsibilities as in effect during the 90-day period immediately preceding the Effective Date, but excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of written notice thereof given by the Executive or a diminution of duties or responsibility on account of the Executive’s incapacity due to physical or mental illness;

(2)any failure by the Company to materially comply with any of the provisions of Section 5 of this Agreement, other than an isolated, insubstantial and inadvertent failure not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Executive;

(3)the Company's requiring the Executive to be based at any office or location other than that described in Section 4 hereof;

(4)any purported termination by the Company of the Executive's employment other than as expressly permitted by this Agreement; or

(5)any failure by the Company to comply with and satisfy Section 13(c) of this Agreement, provided that such successor has received at least ten days’ prior written notice from the Company or the Executive of the requirements of Section 13(c) of the Agreement.

For purposes of this Section 6(c), the written notice shall describe in sufficient detail the reason or condition that the Executive believes would permit the Executive to terminate his employment for Good Reason, and be provided by the Executive to the Company in accordance with 

9

Section 14(b) of this Agreement within ninety (90) days of the initial occurrence of such condition.  Upon receipt of such notice, the Company shall have a period of not less than thirty (30) days to cure the condition, pursuant to reasonable procedures established by the Company consistent with Treas. Reg. §1.409A-1(n).  In the event that such condition is not cured, the Executive’s employment shall terminate no later than thirty (30) days after the expiration of the thirty-day notice period.

(d)Notice of Termination.  Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 14(b) of this Agreement. For purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than fifteen calendar days after the giving of such notice). The failure by the Executive or the Company to set forth in the Notice of Termination any facts or circumstances which contribute to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such facts or circumstances in enforcing the Executive's or the Company's rights hereunder.

(e)Date of Termination. "Date of Termination" means (i) if the Executive's employment is terminated by the Company for Cause, or by the Executive for Good Reason, the date of receipt of the Notice of Termination or any later date specified therein, as the case may be, (ii) if the Executive's employment is terminated by the Company other than for Cause or Disability, the date on which the Company notifies the Executive of such termination, and (iii) if the Executive's employment is terminated by reason of death or Disability, the date of death of the Executive or the Disability Effective Date, as the case may be.

7.Obligations of the Company upon Termination.
(a)Following a Change of Control: Good Reason; Other Than for Cause or Disability. If following a Change of Control and during the Employment Period, the Company terminates the Executive’s employment other than for Cause or Disability or death or the Executive terminates employment for Good Reason, then, subject to the Executive’s satisfaction of the requirements of Sections 11 (Protective Covenants) and 14(g) (release of claims):

(1)the Company shall pay to the Executive in a lump sum in cash within 60 days after the Date of Termination the aggregate of the following amounts (such aggregate being hereinafter referred to as the "Special Termination Amount"):

(i)the sum of (1) the Executive's Annual Base Salary through the Date of Termination to the extent not theretofore paid (“Accrued Unpaid Salary”), (2) the product of (x) the Annual Bonus in effect at such date and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365,  and (3) any accrued vacation pay at the Annual Base Salary rate in effect as of the termination of employment (“Vacation Pay”), in each case to the extent 

10

not theretofore paid (the sum of the amounts described in subclauses (1), (2), and (3) herein shall be called the "Accrued Obligations"); and

11

(ii)the amount equal to the product of (1) two, and (2) the sum of (x) the Executive's Annual Base Salary and (y) the Executive's Annual Bonus in effect at such date; provided, however, that such amount shall be paid in lieu of, and the Executive hereby waives the right to receive, any other amount of benefits under any severance or separation pay plan of the Company, including but not limited to the NextEra Energy, Inc. Executive Severance Benefit Plan); and

(iii)if the Change of Control hereunder is also a “change in ownership,” a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Company within the meaning of Code Section 409A, any compensation previously deferred by the Executive (together with any accrued interest or earnings thereon) including, without limitation, compensation, bonus, incentive compensation or awards deferred under the NextEra Energy, Inc. Deferred Compensation Plan or incentive compensation or awards deferred under the FPL Group, Inc. Long-Term Incentive Plan of 1985, the FPL Group, Inc. Long-Term Incentive Plan of 1994, or pursuant to any individual deferral agreement; provided that, for the avoidance of doubt, if the Change of Control hereunder is not any such event within the meaning of Code Section 409A, payment of the foregoing amounts shall be made as soon practicable consistent with Code Section 409A;

(2)each outstanding performance stock-based award granted to the Executive prior to the Change of Control shall be fully vested and earned at a deemed achievement level equal to the higher of (x) the targeted level of performance for such award or (y) the average level (expressed as a percentage of target) of achievement in respect of similar performance stock-based awards which matured over the three fiscal years immediately preceding the year in which the Change of Control occurred; payment of each such vested award shall be made to the Executive, in the form described below, as soon as practicable following the Date of Termination consistent with Code Section 409A;

(3)all other outstanding stock-based awards granted to the Executive prior to the Change of Control shall be fully vested and earned;

(4)any outstanding option, stock appreciation right, and other outstanding award in the nature of a right that may be exercised that was granted to the Executive prior to the Change of Control and which was not previously exercisable and vested shall become fully exercisable and vested;

(5)the restrictions and forfeiture conditions applicable to any outstanding award granted to the Executive prior to the Change of Control under the NextEra Energy, Inc. Amended and Restated 2011 Long Term Incentive Plan (or its successor) (including, without limitation, performance share awards, stock option grants and restricted stock awards), or other plan providing for the grant of equity compensation for executive officers. shall lapse and such award shall be deemed fully vested. 

(6)for  an 24-month period commencing on the Date of Termination (the "Continuation Period") (which period shall be concurrent with the applicable continuation period set forth in Code Section 4980B), or such longer period as any plan, program, practice or policy may provide, the Company shall continue benefits to the Executive and/or the Executive's family at least equal to those 

12

which would have been provided to them in accordance with the plans, programs, practices and policies described in Sections 5(e) and 5(g) of this Agreement if the Executive's employment had not been terminated, in accordance with the most favorable plans, practices, programs or policies of the Company and its Affiliated Companies applicable generally to other peer executives and their families during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its Affiliated Companies and their families, provided, however, that if the Executive becomes reemployed with another employer and is eligible to receive medical or other welfare benefits under another employer provided plan, the medical and other welfare benefits described herein shall be secondary to those provided under such other plan during such applicable period of eligibility. For purposes of determining eligibility of the Executive for retiree benefits pursuant to such plans, practices, programs and policies, the Executive shall be considered to have remained employed until the end of the Continuation Period and to have retired on the last day of such period. In addition to, and notwithstanding anything to the contrary in, the foregoing provisions of this subparagraph (6), and to the extent that the benefit referred to in this sentence is more favorable to the Executive than the benefit conferred by the foregoing provisions of this subparagraph (6), upon termination of employment, the Executive shall be entitled without limitation as to period to enroll in Access Only Benefits, as defined in the NextEra Energy, Inc. Retiree Benefits Plan as amended and restated effective January 1, 2013 (the “Retiree Benefits Plan”), or in a comparable medical benefits arrangement, if the Executive satisfies the eligibility requirements as stated in Appendix B to the Retiree Benefits Plan as in effect as of April 1, 2020, even if Access Only Benefits, or comparable medical benefits, are no longer being provided to other employees of the Company; provided, that such medical benefits shall be provided to the Executive to the extent that such coverage is available under the Company’s health, dental and vision plans or can be obtained on commercially reasonable terms;

(7)to the extent not theretofore paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive pursuant to this Agreement or otherwise under any plan, program, policy or practice or contract or agreement of the Company and its Affiliated Companies, but excluding solely for purposes of this Section 7(a)(7) (and subsequent sections hereof which make reference to payments of amounts or benefits described in this Section 7(a)(7)) amounts waived by the Executive pursuant to Section 7(a)(1)(ii); and

(8)the Company shall provide the Executive with outplacement services commensurate with those provided to terminated executives of comparable level made available through and at the facilities of a reputable and experienced vendor.  

(b)Following an Effective Date and Prior to a Change of Control: Good Reason; Other Than for Cause or Disability. If, following an actual Effective Date (i.e., not a Deemed Effective Date) and prior to a Change of Control, the Company terminates the Executive's employment during the Employment Period other than for Cause or Disability or death or the Executive terminates employment for Good Reason, then the Company shall provide the Executive with the payments and benefits described under Sections 7(a)(1) through (8), except that for purposes of the benefits under Section 7(a)(2), the applicable averaging period shall be the three fiscal years immediately preceding the year in which the Date of Termination occurs.

13

 
(c)Deemed Effective Date. If the Executive's employment terminates after a Deemed Effective Date as defined in, and under the circumstances described in, the second sentence of Section 1 hereof, then the Company shall provide the Executive with the payments and benefits described under Sections 7(a)(1) through (8).

(d)Death.  Upon the Executive's death during the Employment Period, this Agreement shall terminate without further obligations to the Executive's legal representatives under this Agreement, other than for payment of Accrued Obligations and the timely payment or provision of the benefits described in Sections 7(a)(6) and 7(a)(7) (the "Other Benefits"). All Accrued Obligations shall be paid to the Executive's estate or beneficiary, as applicable, in a lump sum in cash within 30 days of the Date of Termination. The term "Other Benefits" as utilized in this Section 7(d) shall include, without limitation, and the Executive's family shall be entitled to receive, benefits at least equal to the most favorable benefits provided by the Company and any of its Affiliated Companies to surviving families of peer executives of the Company and such Affiliated Companies under such plans, programs, practices and policies relating to family death benefits, if any, as in effect with respect to other peer executives and their families at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive and/or the Executive's family, as in effect on the date of the Executive's death with respect to other peer executives of the Company and its Affiliated Companies and their families.

(e)Disability. If the Executive's employment is terminated by reason of the Executive's Disability during the Employment Period, this Agreement shall terminate without further obligations to the Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits (as defined in Section 7(d)). All Accrued Obligations shall be paid to the Executive in a lump sum in cash within 30 days of the Date of Termination. The term "Other Benefits" as utilized in this Section 7(e) shall also include, and the Executive shall be entitled after the Disability Effective Date to receive, disability and other benefits at least equal to the most favorable of those generally provided by the Company and its Affiliated Companies to disabled executives and/or their families in accordance with such plans, programs, practices and policies relating to disability, if any, as in effect generally with respect to other peer executives and their families at any time during the 90-day period immediately preceding the Effective Date or, if more favorable to the Executive and/or the Executive's family, as in effect at any time thereafter generally with respect to other peer executives of the Company and its Affiliated Companies and their families.

(f)Cause; Other Than for Good Reason.  If the Executive's employment shall be terminated for Cause during the Employment Period, this Agreement shall terminate without further obligations to the Executive other than the obligation to pay to the Executive Annual Base Salary through the Date of Termination plus the amount of any compensation previously deferred by the Executive (under the terms set forth in, and pursuant to the elections made under, the applicable deferred compensation plan or arrangement), in each case to the extent theretofore unpaid. If the Executive terminates employment during the Employment Period, excluding a termination for Good Reason, this Agreement shall terminate without further obligations to the Executive, other than Accrued Base Salary and Vacation Pay, and the timely payment or provision of benefits pursuant to the last sentence of Section 7(a)(6) 

14

and Section 7(a)(7). In such case, Accrued Base Salary and Vacation Pay shall be paid to the Executive in a lump sum in cash within 30 days of the Date of Termination. 

(g)Payment Schedule. Notwithstanding anything to the contrary in this Agreement, to the extent required to comply with Code Section 409A(a)(2)(B), (i) if the Executive's termination of employment does not constitute a "separation from service" within the meaning of Code Section 409A, any taxable payment or benefit which becomes due under this Agreement as a result of such termination of employment shall be deferred to the earliest date on which the Executive has a "separation from service” within the meaning of Code Section 409A; and (ii) if the Executive is deemed to be a “specified employee” for purposes of Code Section 409A(a)(2)(B), payments due to him that would otherwise have been payable at any time during the six-month period immediately following separation from service (as defined for purposes of Code Section 409A) shall not be paid prior to, and shall instead be payable in a lump sum as soon as practicable following, the expiration of such six-month period. Any amounts deferred under this Section 7(g) shall bear interest from the date originally scheduled to be paid through and including the date of actual payment at 120% of the applicable federal long-term rate (as prescribed under Code Section 1274(d)) per annum, compounded quarterly. In addition to the foregoing, payments that are or become due on account of a Deemed Effective Date shall be made at the time otherwise provided in this Agreement or, if later, the earlier of six months following the Date of Termination and the date of occurrence of a “change in control event” (within the meaning of Code Section 409A and the regulations thereunder).

8.Non-Exclusivity of Rights.
Except as otherwise expressly provided for in this Agreement, nothing in this Agreement shall prevent or limit the Executive's continuing or future participation in any plan, program, policy or practice provided by the Company or any of its Affiliated Companies and for which the Executive may qualify (other than any benefits under any severance or separation pay plan of the Company, including but not limited to the NextEra Energy, Inc. Executive Severance Benefit Plan), nor shall anything herein limit or otherwise affect such rights as the Executive may have under any contract or agreement with the Company or any of its Affiliated Companies. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the Company or any of its Affiliated Companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement and consistent with Code Section 409A.

9. Full Settlement.
Except as required under the NextEra Energy, Inc. Incentive Compensation Recoupment Policy or any similar or successor policy or practice of the Company, the Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive or others. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and, except as otherwise expressly provided for in this Agreement, such amounts shall not be reduced whether or not the Executive obtains other employment. To the extent the Executive prevails on at least one material 

15

claim, the Company agrees to pay, to the fullest extent permitted by law (but only to the extent consistent with Code Section 409A), all legal fees and expenses which the Executive may reasonably incur as a result of any legal proceedings by the Company, the Executive, or others, as to the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive about the amount of any payment pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Code Section 7872(f)(2)(A).

16

10. Parachute Payments.
(a)Anything in any section of this Agreement other than this Section 10 to the contrary not- withstanding, in the event it shall be determined that any Payment (as hereinafter defined) would be subject to the Excise Tax (as hereinafter defined), the right to receive any Payment under this Agreement shall be reduced if but only if:

(i)such right to such Payment, taking into account all other Payments to or for Participant, would cause any Payment to the Participant under this Agreement to be considered a "parachute payment" within the meaning of Code Section 280G(b)(2) as then in effect; and

(ii)as a result of receiving a parachute payment and paying any applicable tax (including Excise Tax thereon), the aggregate after-tax amounts received by the Participant from the Company under this Agreement and all Payments would be less than the maximum after-tax amount that could be received by Participant without causing any such Payment to be considered a parachute payment.

In the event that the receipt of any such right to Payment under this Agreement, in conjunction with all other Payments, would cause the Participant to be considered to have received a parachute payment under this Agreement that would have the effect of decreasing the after-tax amount received by the Participant as described in clause (ii) of the preceding sentence, then the amounts payable under this Agreement shall be reduced so that the Parachute Value of all Payments, in the aggregate, equals the Safe Harbor Amount.

To the extent that the payment of any compensation or benefits to Executive from the Company is required to be reduced by this Section 10, such reduction shall be implemented by determining the “Parachute Payment Ratio” (as hereinafter defined) for each parachute payment and then reducing the parachute payments in order beginning with the parachute payment with the highest Parachute Payment Ratio. For parachute payments with the same Parachute Payment Ratio, such parachute payments shall be reduced based on the time of payment of such parachute payments, with amounts having later payment dates being reduced first. For parachute payments with the same Parachute Payment Ratio and the same time of payment, such parachute payments shall be reduced on a pro rata basis (but not below zero) prior to reducing parachute payments with a lower Parachute Payment Ratio. 
(b)Definitions. The following terms shall have the following meanings for purposes of this Section 10.

(i)“Excise Tax” shall mean the excise tax imposed by Code Section 4999, together with any interest or penalties imposed with respect to such excise tax.
(ii)“Parachute Payment Ratio” shall mean a fraction the numerator of which is the value of the applicable parachute payment for purposes of Code Section 280G and the denominator of which is the intrinsic value of such parachute payment.

17

(iii)“Parachute Value” of a Payment shall mean the present value as of the date of the change of control for purposes of Code Section 280G of the portion of such Payment that constitutes a “parachute payment” under Code Section 280G(b)(2), as determined for purposes of determining whether and to what extent the Excise Tax will apply to such Payment.
(iv)A “Payment” shall mean any payment or distribution in the nature of compensation (within the meaning of Code Section 280G(b)(2)) to or for the benefit of the Executive, whether paid or payable pursuant to this Agreement or otherwise.
(v)The “Safe Harbor Amount” means 2.99 times the Executive’s “base amount,” within the meaning of Code Section 280G(b)(3).

11. Protective Covenants.
(a)Confidential Information. (i) The Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data relating to the Company or any of its Affiliated Companies, and their respective businesses, which shall have been obtained by the Executive during the Executive's employment by the Company or any of its Affiliated Companies and which shall not be or become public knowledge (other than by acts of the Executive or representatives of the Executive in violation of this Agreement). After termination of the Executive's employment with the Company, the Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, communicate or divulge any such information, knowledge or data to anyone other than the Company and those designated by it. 
    (ii) The Executive is  hereby notified in accordance with the Defend Trade Secrets Act of 2016 that the Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.  The Executive is further notified that if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the Company’s trade secrets to the Executive’s attorney and use the trade secret information in the court proceeding if the Executive: (a) files any document containing the trade secret under seal; and (b) does not disclose the trade secret, except pursuant to court order.  
(b)Noncompetition.  During Employment Period and for a two-year period following the termination of the Executive’s employment with the Company, the Executive agrees not to (i) compete or attempt to compete for, or act as a broker or otherwise participate in, any projects in which the Company has at any time done any work or undertaken any development efforts, or (ii) directly or indirectly solicit any of the Company’s customers, vendors, contractors, agents, or any other parties with which the Company has an existing or prospective business relationship, for the benefit of the Executive or for the benefit of any third party, nor shall the Executive accept consideration or negotiate or enter into agreements with such parties for the benefit of the Executive or any third party.

18

(c)Non-solicitation.  During the Employment Period and for a two-year period following the termination of the Executive's employment with the Company, the Executive shall not, directly or indirectly, on behalf of the Executive or for any other business, person or entity, entice, induce or solicit or attempt to entice, induce or solicit any employee of the Company or its Subsidiaries or other Affiliates to leave the Company's employ (or the employ of such Subsidiary or other Affiliate) or to hire or to cause any employee of the Company to become employed for any reason whatsoever.
(d)Non-disparagement.  The Executive shall not, at any time or in any way, disparage the Company or its current or former officers, directors, and employees, orally or in writing, or make any statements that may be derogatory or detrimental to the Company’s good name or business reputation.
(e)Cooperation.  The Executive agrees that certain matters in which the Executive may have been involved during the before and during the Employment Period may necessitate the Executive’s cooperation in the future.  Accordingly, as a further condition to the Executive’s retention of benefits under this Agreement, to the extent reasonably requested by the Company, the Executive will cooperate with the Company and any Affiliate in connection with matters arising out the Executive’s service to the Company and its Affiliates; provided, however, that the Company or its Affiliates will make reasonable efforts to minimize disruption of the Executive’s other activities.  The Company will reimburse the Executive for reasonable expenses incurred in connection with such cooperation and, to the extent the Executive is required to spend substantial time on such matters, the Company will compensate the Executive at an hourly rate based on the sum of the Executive’s annual base salary and annual target cash incentive opportunity in effect immediately prior to the Executive’s termination of employment.  
(f)No Remedy.  The Executive acknowledges that the Company would not have an adequate remedy at law for monetary damages if the Executive breaches these Protective Covenants. Therefore, in addition to all remedies to which the Company may be entitled for a breach or threatened breach of these Protective Covenants, including but not limited to monetary damages, the Company shall be entitled to specific enforcement of these Protective Covenants and to injunctive or other equitable relief as a remedy for a breach or threatened breach. In addition, upon any breach of these Protective Covenants or any separate confidentiality agreement or confidentiality provision between the Company and the Executive, the Executive will be required to repay to the Company any amounts received pursuant to this Agreement (other than Accrued Unpaid Salary and Vacation Pay), and the Executive’s rights to receive any other unpaid compensation under this Agreement shall be forfeited.

12. Indemnification. 
The Company will, to the fullest extent permitted by law, indemnify the Executive in accordance with the terms of Article VI of the Company’s bylaws as in effect on the date hereof, a copy of which Article VI is attached to this Agreement as Annex A and made a part hereof by this reference. This indemnification provision shall survive the expiration or other termination of this Agreement.  
13. Successors.
(a)This Agreement is personal to the Executive and without the prior written consent of the Company shall not be assignable by the Executive other than by will or the laws of descent and 

19

distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive's legal representatives.

(b)This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

(c)The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.

14. Miscellaneous.
(a)This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be amended or modified other than by a written agreement executed by the parties hereto or their respective successors and legal representatives.

(b)All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

If to the Executive:

Robert P. Coffey
[Home Address]

If to the Company:

NextEra Energy, Inc. 
700 Universe Boulevard
Juno Beach, Florida 33408
Attention: Chairman & Chief Executive Officer

or such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.
(c)The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

20

(d)The Company may withhold from any amounts payable under this Agreement such Federal, state or local taxes as shall be required to be withheld pursuant to any applicable law or regulation.

(e)The Executive's or the Company's failure to insist upon strict compliance with any provision hereof or any other provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for Good Reason pursuant to Section 6(c) of this Agreement, shall not be deemed to be a waiver of such provision or right or any other provision  or right of this Agreement.

(f)The Executive and the Company acknowledge that, except as may otherwise be provided under this Agreement or any other written agreement between the Executive and the Company, the employment of the Executive by the Company is "at will" and the Executive’s employment may be terminated by either the Executive or the Company at any time. Moreover, except as provided herein in the case of a Deemed Effective Date, if prior to the Effective Date, (i) the Executive's employment with the Company terminates, or (ii) there is a material diminution in the Executive's position (including titles and reporting requirements), authority, duties, and responsibilities with the Company or its Affiliated Companies, then the Executive shall have no rights under this Agreement. From and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof, and in furtherance but not in limitation of this, the Executive hereby waives the right to receive any benefits under any severance or separation pay plan of the Company, including but not limited to the NextEra Energy, Inc. Executive Severance Benefit Plan.

(g)The Executive and the Company acknowledge that this Agreement contains the full and complete expression of the rights and obligations of the parties with respect to the matters contained in the Agreement. This Agreement supersedes any and all other agreements, written or oral, made by the parties with respect to the matters contained in the Agreement.

Notwithstanding anything herein to the contrary, and except in the case of death, it shall be a condition to the Executive receiving any payments or benefits under this Agreement that the Executive shall have (a) executed, delivered to the Company and not revoked a release of claims against the Company, such release to be in the Company’s then standard form of release; and (b) executed and delivered to the Company resignations of all officer and director positions the Executive holds with the Company or its Affiliated Companies, in each case no later than forty-five (45) days after the Date of Termination unless there is a genuine dispute as to the Executive’s substantive rights under this Agreement within the meaning of Treasury Regulation 1.409A-3(g) (or any successor provision). If the Executive’s timing of the delivery of the release of claims in accordance with this paragraph could result in the payments that are treated as deferred compensation under Code Section 409A either being paid in the then current calendar year or the calendar year following the Executive’s Date of Termination, then, notwithstanding any contrary provision of this Agreement, the affected payments instead shall automatically and mandatorily be paid in the calendar year following the calendar year in which the Date of Termination occurs.

The Executive and the Company acknowledge that the benefits and payments provided under this Agreement are intended to comply fully with the requirements of Code Section 409A. This 

21

Agreement shall be construed and administered as necessary to comply with Code Section 409A and shall be subject to amendment in the future, in such a manner as the Company may deem necessary or appropriate to attain compliance; provided, however, that any such amendment shall provide the Executive with benefits and payments that are substantially economically equivalent to the benefits and payments that would have been made to the Executive absent such amendment and the requirements of Code Section 409A.

22

IN WITNESS WHEREOF, the Executive has hereunto set the Executive's hand and the Company has caused Executive Retention Employment Agreement to be executed in its name on its behalf, all as of June 14, 2021.

															
					
			By:	ROBERT P. COFFEY
				Robert P. Coffey
					
					
				NEXTERA ENERGY, INC.
					
					
			By:	JAMES L. ROBO
				James L. Robo
				Chairman and Chief Executive Officer

23

ANNEX A TO THE
EXECUTIVE RETENTION EMPLOYMENT AGREEMENT

NEXTERA ENERGY, INC. AMENDED AND RESTATED BYLAWS ARTICLE VI.
INDEMNIFICATION/ADVANCEMENT OF EXPENSES

Section 1.  Right to Indemnification. Each person who was or is made a party or is threatened to be made a party to or was or is called as a witness or was or is otherwise involved in any Proceeding in connection with his or her status as an Indemnified Person, shall be indemnified and held harmless by the Company to the fullest extent permitted under the Florida Business Corporation Act (the "Act"), as the same now exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than the Act permitted the Company to provide prior to such amendment). Such indemnification shall cover all expenses incurred by an Indemnified Person (including, but not limited to, attorneys' fees and other expenses of litigation) and all liabilities and losses (including, but not limited to, judgments, fines, ERISA or other excise taxes or penalties and amounts paid or to be paid in settlement) incurred by such person in connection therewith.

Notwithstanding the foregoing, except with respect to indemnification specified in Section 3 of this Article VI, the Company shall indemnify an Indemnified Person in connection with a Proceeding (or part thereof) initiated by such person only if authorization for such Proceeding (or part thereof) was not denied by the board of directors of the Company prior to 60 days after receipt of notice thereof from such person.

For purposes of this Article VI:

(i)a "Proceeding" is an action, suit or proceeding, whether civil, criminal, administrative or investigative, and any appeal therefrom;

(ii)an "Indemnified Person" is a person who is, or who was (whether at the time the facts or circumstances underlying the Proceeding occurred or were alleged to have occurred or at any other time), (A) a director or officer of the Company, (B) a director, officer or other employee of the Company serving as a trustee or fiduciary of an employee benefit plan of the Company, (C) an agent or non-officer employee of the Company as to whom the Company has agreed to grant such indemnity, or (D) serving at the request of the Company in any capacity with any entity or enterprise other than the Company and as to whom the Company has agreed to grant such indemnity.

1

Section 2. Expenses. Expenses, including attorneys' fees, incurred by an Indemnified Person in defending or otherwise being involved in a Proceeding in connection with his or her status as an Indemnified Person shall be paid by the Company in advance of the final disposition of such Proceeding, including any appeal therefrom, (i) in the case of (A) a director or officer, or former director or officer, of the Company or (B) a director, officer or other employee, or former director, officer or other employee, of the Company serving as a trustee or fiduciary of any employee benefit plan of the Company, upon receipt of an undertaking ("Undertaking") by or on behalf of such person to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Company; or (ii) in the case of any other Indemnified Person, upon such terms and as the board of directors, the chairman of the board or the president of the Company deems appropriate.

Notwithstanding the foregoing, in connection with a Proceeding (or part thereof) initiated by such person, except a Proceeding authorized by Section 3 of this Article VI, the Company shall pay said expenses in advance of final disposition only if authorization for such Proceeding (or part thereof) was not denied by the board of directors of the Company prior to 60 days after receipt of a request for such advancement accompanied by an Undertaking.

A person to whom expenses are advanced pursuant to this Section 2 shall not be obligated to repay such expenses pursuant to an Undertaking until the final determination of any pending Proceeding in a court of competent jurisdiction concerning the right of such person to be indemnified or the obligation of such person to repay pursuant to such Undertaking.
Section 3. Protection of Rights. If a claim for indemnification under Section 1 of this Article VI is not promptly paid in full by the Company after a written claim has been received by the Company or if expenses pursuant to Section 2 of this Article VI have not been promptly advanced after a written request for such advancement accompanied by an Undertaking has been received by the Company (in each case, except if authorization thereof was denied by the board of directors of the Company as provided in Article VI, Section 1 and Section 2, as applicable), the Indemnified Person may at any time thereafter bring suit against the Company to recover the unpaid amount of the claim or the advancement of expenses. If successful, in whole or in part, in such suit, such Indemnified Person shall also be entitled to be paid the reasonable expense thereof. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any Proceeding in advance of its final disposition where the required Undertaking has been tendered to the Company) that indemnification of the Indemnified Person is prohibited by law, but the burden of proving such defense shall be on the Company. Neither the failure of the Company (including its board of directors, independent legal counsel, or its shareholders) to have made a 
2

determination, if required, prior to the commencement of such action that indemnification of the Indemnified Person is proper in the circumstances, nor an actual determination by the Company (including its board of directors, independent legal counsel, or its shareholders) that indemnification of the Indemnified Person is prohibited, shall be a defense to the action or create a presumption that indemnification of the Indemnified Person is prohibited.
Section 4. Miscellaneous.

(i)Power to Request Service and to Grant Indemnification. The chairman of the board or the president or the board of directors may request any director, officer, agent or employee of the Company to serve as its representative in the position of a director or officer (or in a substantially similar capacity) of an entity or enterprise other than the Company, and may grant to such person indemnification by the Company as described in Section 1 of this Article VI.

(ii)Non-Exclusivity of Rights. The rights conferred on any person by this Article VI shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Charter, bylaw, agreement, vote of shareholders or disinterested directors or otherwise. The board of directors shall have the authority, by resolution, to provide for such indemnification of employees or agents of the Company or others and for such other indemnification of directors, officers, employees or agents as it shall deem appropriate.

(iii)Insurance Contracts and Funding. The Company may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of or person serving in any other capacity with, the Company or another corporation, partnership, joint venture, trust or other enterprise (including serving as a trustee or fiduciary of any employee benefit plan) against any expenses, liabilities or losses, whether or not the Company would have the power to indemnify such person against such expenses, liabilities or losses under the Act. The Company may enter into contracts with any director, officer, agent or employee of the Company in furtherance of the provisions of this Article VI, and may create a trust fund, grant a security interest or use other means (including, without limitation, a letter of credit) to ensure the payment of such amounts as may be necessary to effect the advancing of expenses and indemnification as provided in this Article VI.
(iv)Contractual Nature. The provisions of this Article VI shall continue in effect as to a person who has ceased to be a director, officer, agent or employee and shall inure to the benefit of the heirs, executors and administrators of such person. This Article VI shall be deemed to be a contract between the Company and each person who, at any time that this Article VI is in effect, serves or served in any capacity which entitles him or her to indemnification hereunder and any repeal or other modification of this Article VI or any repeal or modification of the Act, or any other applicable law shall not limit any rights of indemnification with respect to Proceedings in connection with which he or she is an Indemnified Person, or advancement of expenses in connection with such Proceedings, then existing or arising out of events, acts or omissions occurring prior to such repeal or modification, including without limitation, the right to indemnification for Proceedings, 
3

and advancement of expenses with respect to such Proceedings, commenced after such repeal or modification to enforce this Article VI with regard to Proceedings arising out of acts, omissions or events arising prior to such repeal or modification.

(v)Savings Clause. If this Article VI or any portion hereof shall be invalidated or held to be unenforceable on any ground by any court of competent jurisdiction, the decision of which shall not have been reversed on appeal, the Company shall nevertheless (A) indemnify each Indemnified Person as to costs, charges and expenses (including attorneys' fees), judgments, fines and amounts paid in settlement and (B) advance expenses in accordance with Section 2 of this Article VI, in each case with respect to any Proceeding in connection with which he or she is an Indemnified Person, including an action by or in the right of the Company, to the fullest extent permitted by any applicable portion of this Article VI that shall not have been invalidated or held to be unenforceable and as permitted by applicable law.
4Exhibit
10.9

 

Page 1 of 14 

 

Quality
Agreement

 

between

 

Biofrontera
Incorporated

hereinafter
referred to as “Biofrontera”

 

and

 

Biofrontera
Pharma GmbH

hereinafter
referred to as “Pharma”

 

    	Confidential

    	Page 2 of 14

    

 

APPROVALS

 

The
information contained in this Agreement of Responsibilities has been reviewed and approved by the following individuals:

 

	Approved
    By:	 	Effective
    Date
	 	 	 
	Biofrontera
    Incorporated:	 	 
	 	 	 
	/s/
    Monica Tamborini	 	11/1/2016
	[Monica
                                            Tamborini]

    [COO]

    Biofrontera
    Inc.
	 	(Date
    Signed)
	 	 	 
	Biofrontera
    Incorporated:	 	 
	 	 	 
	/s/
    Darrell T. Lowman	 	11/01/2016
	[Darrell
                                            T. Lowman]

    [Quality
    Assurance Director]

    Biofrontera
    Inc.
	 	(Date
    Signed)
	 	 	 
	Biofrontera
    Pharma GmbH	 	 
	 	 	 
	/s/
    Hermann Lübbert	 	27-10-16
	[Hermann
                                            Lübbert]

    [CEO]

    Biofrontera
    Pharma GmbH
	 	(Date
    Signed)
	 	 	 
	Biofrontera
    Pharma GmbH	 	 
	 	 	 
	/s/
    Wiebke Meyer-Wendt	 	13
    Oct. 2016
	[Wiebke
                                            Meyer-Wendt]

    [Director
    Quality Management]

    Biofrontera
    Pharma GmbH
	 	(Date
    Signed)

 

    	Confidential

    	Page 3 of 14

    

 

TABLE
OF CONTENTS

 

	1.	Recital	4
	2.	Purpose
    and Scope of the Quality Agreement	4
	3.	Terms
    of Agreement	4
	4.	Abbreviations	5
	5.	Product
    and Services	5
	6.	Quality
    Systems 	6
	7.	Documentation
    Control	7
	8.	Purchasing
    and Material Control System 	7
	9.	Laboratory
    Testing and Quality Controls System	8
	10.	Facility
    and Equipment Controls	9
	11.	Production
    and Process Controls	9
	12.	Control
    of Non-Conforming Product, Disposition and Rework	9
	13.	Corrective
    and Preventive Action	10
	14.	Handling,
    Storage, Distribution, Installation and Servicing	10
	15.	Shipment	10
	16.	Records	11
	17.	Complaints
    and Pharmacovigilance	11
	18.	Annual
    Product Reviews and Annual Reports	11
	19.	Company
    Contacts	12
	Attachment
    I – Product(s)	13
	Attachment
    II – Controlled documents to be provided to each other	14

 

 

    	Confidential

    	Page 4 of 14

    

 

	1.	Recital

 

The
Parties to this quality agreement are also Parties to a License and Supply Agreement (LSA) according to which Pharma grants a license
to Biofrontera for the import, distribution and marketing in the USA of the drug product and medical device listed in Attachment 1.

 

According
to the agreement, Pharma is obliged to deliver Products of the quality and according to the specifications agreed upon with the FDA in
the respective approvals.

 

Approval
Holder of the drug / device combination is Biofrontera Bioscience GmbH, which also owns all IP on the drug. IP on the device is owned
by Pharma. Biofrontera Bioscience GmbH has provided Pharma with an exclusive license to manufacture and market the Products, including
the right for sublicensing. In this role, Pharma has granted the license to Biofrontera, which forms the basis of this Quality Agreement.
All commercial aspects are ruled by the License and Supply Agreement between the Parties to this Quality Agreement.

 

Biofrontera
is obliged to market and distribute the product according to label / approval and perform some local activities on behalf of the Approval
Holder. For instance, Biofrontera is responsible for ensuring that Ameluz is stored and transported at the temperature defined in the
Prescribing Information and sold exclusively to customers qualified to receive a drug product or medical device.

 

	2.	Purpose
    and Scope of the Quality Agreement

 

	 	2.1.	Purpose
    of this agreement is to define and document quality and regulatory responsibilities including, but not limited to manufacturing,
    packaging, labeling, complaints, change control and any applicable requirements. 
	 	 	 
	 	2.2.	This
    agreement does not define the forecasting, ordering, delivery, or pricing requirements for either party. This agreement does not
    define the specifications for the products or services covered.
	 	 	 
	 	2.3.	The
    scope of the quality agreement applies to the products listed in Attachment 1.
	 	 	 
	 	2.4.	This
    Agreement supersedes any previous written quality agreement between the parties.
	 	 	 
	 	2.5.	The
    effective date of this agreement shall be the date of the last signature.

 

	3.	Terms
    of Agreement

 

	 	3.1.	It
    is acknowledged that this will be a continuously evolving process, requiring review at a minimum, for each additional new Product
    whose manufacturing, testing, packaging, distribution and/or marketing responsibilities is shared between Biofrontera and Pharma.
    
	 	 	 
	 	3.2.	Failure
    to perform all or part of the Agreement may result in discontinuation of services or termination of contract by the party which is
    not in default, if the issue is not corrected with a reasonably agreed timeframe. 
	 	 	 
	 	3.3.	If
    material differences exist between this Agreement and Biofrontera’s Standard Operating Procedures, this Agreement shall control
    but Biofrontera shall notify Pharma of such differences and the Parties agree to make good faith efforts to resolve such material
    differences. Attachment 2 contains a list of controlled documents which Biofrontera and Pharma shall provide to each other.

 

    	Confidential

    	Page 5 of 14

    

 

	4.	Abbreviations

 

	 	ADE
    / AE 	Adverse
    Drug Event / Adverse Event
	 	APR	Annual
    Product Review
	 	CAPA	Corrective/Preventive
    Action
	 	CFR	Code
    of Federal Regulations
	 	FDA	Food
    and Drug Administration
	 	GMP	Good
    Manufacturing Practice
	 	HVAC	Heating,
    Ventilation and Air Conditioning
	 	LSA	License
    and Supply Agreement
	 	MDR	Medical
    Device Reporting
	 	OPDP	Office
    of Prescription Drug Promotion
	 	PDMA	Prescription
    Drug Marketing Act of 1987
	 	QMS	Quality
    Management System
	 	SCAR
    	Supplier
    Corrective Action Request

 

	5.	Product
    and Services

 

	 	5.1.	Product
    Classification(s) [Check all that apply]

 

☒
Drug        ☒ Medical        ☐
Device      ☐ Cosmetic           ☐ Other

 

	 	5.2.	Services
    [Check all that apply]

 

Biofrontera
Inc.

 

	 	☐	Owner/Specification
    Developer
	 	☐	Relabeler
    or Repackager
	 	☒	Distributor
	 	☐	Contract
    manufacturer
	 	☐	Contract
    sterilizer
	 	☐	Initial
    Importer
	 	☒	Importer
    of Drug Product
	 	☒	Licensee

 

Biofrontera
Pharma (also representing Biofrontera Bioscience GmbH)

 

	 	☒	Owner/Specification
    Developer
	 	☐ 	Relabeler
    or Repackager
	 	☐	Distributor
	 	☒	Contract
    manufacturer
	 	☐	Contract
    sterilizer
	 	☐	Initial
    Importer
	 	☒	Importer
    of Medical Device
	 	☒	Licenser
    (on behalf of NDA sponsor, Biofrontera Bioscience GmbH)

 

	 	5.3.	Regulatory/Quality
    control

 

☒
21 CFR 820, QSR (Quality System Regulations)

☒ 21
CFR 210, 211, cGMP (Current Good Manufacturing Practices)

 

    	Confidential

    	Page 6 of 14

    

 

	6.	Quality
    Systems

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	6.1.
    	 	☒	 	☒	 	Quality
    System - A quality system shall be established, documented and maintained as a means of ensuring that Product conforms to specifications
	6.2.
    	 	☒	 	☒	 	Quality
    Manual that includes a quality policy shall be established and both parties shall ensure that the policy is understood, implemented
    and maintained at all level of the organization.
	6.3.
    	 	☒	 	☒	 	Quality
    Audit – Establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance
    with the established cGMP and QS requirements.
	6.3.1.
    	 	☐	 	☒	 	Reserves
    the right to audit Pharma premises and all documentation used in the manufacturing, packaging and testing of the Product during normal
    business hours with reasonable written notice and causing minimum disruption to Pharma operations.
	5.3.2	 	☒	 	☐	 	Reserves
    the right to audit BIOFRONTERA premises and all documentation related to marketing and distribution of products in the US during
    normal business hours with reasonable written notice and causing minimum disruption to BIOFRONTERA operations.
	6.3.2.
    	 	☒		☒	 	Provide
    a written detailed report of audit observations and conclusions.
	6.3.3.
    	 	☒	 	☒	 	Provide
    a written response to audit observations and conclusions within thirty (30) days of receipt of a written audit report.
	6.3.4.
    	 	☒	 	☒	 	Provide,
    as appropriate, proof of corrective/preventive action(s) implemented to address audit observations
	6.4.
    	 	☐	 	☒	 	Recall,
    Removal - Maintain Product records including lot and serial numbers, as applicable and shipping information to ensure traceability
    in the event a recall or market withdrawal is required. Support Stop Shipment Notification, Notice of Recall, and Replacement log.
	6.4.1.
    	 	☒	 	☐	 	Primary
    responsibility for recall activities including but not limited to providing Notice of Recall Product Recall, Recall Coordinator,
    FDA recall submission, periodic recall status reporting, recall termination and closing. 
	6.5.
    	 	☒	 	☒	 	Qualifications
                                            and Training - Procedures shall be established to ensure that all personnel have adequate
                                            combination of education, experience and documented training to perform job functions.

    Training
    shall be conducted and documented.

	6.6.
    	 	☒	 	☒	 	Regulatory
    Agency Inspections - Inform the other Party within one (1) business day in case of warning letters and major quality issues that
    may impact the Product and represent a risk for the patient or the user.
	6.7.
    	 	☒	 	☒	 	Regulatory
    Agency Communications - Provide copies (redacted, if required) of regulatory agency 483s, Warning Letters and other Notices relating
    to its activities associated with the product.
	6.8.
    	 	☒		☒	 	Establishment
    Registration and Listing - Maintain current FDA Establishment Registration(s) and listing for all applicable activities.
	6.9.
    	 	☐	 	☒	 	State
    Licensing – Maintain state licenses for the distribution of drug products and medical devices as applicable and fulfil
    all state reporting obligations.
	6.10.
    	 	☐	 	☒	 	Customer
    Qualification - Implement processes to ensure that products are distributed to qualified customers only
	6.11.
    	 	☐	 	☒	 	Drug
    Sample Distribution – Implement processes to ensure that drug samples are distributed according to the requirements dictated
    in the Prescription Drug Marketing Act (PDMA). Compliance with PDMA requirements for documentation and reporting to FDA and the States
    where applicable. 
	6.12.
    	 	☐	 	☒	 	Sunshine
    Act – fulfill all obligations of the Physician Payments Sunshine Act, including appropriate documentation and reporting.
	6.13.
    	 	☐	 	☒	 	Compliance
    with all federal and state laws related to the distribution of drug products and medical devices.

 

    	Confidential

    	Page 7 of 14

    

 

	7.	Documentation
    Control

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	7.1	 	☒	 	☒	 	Implement
    and maintain an effective change control system in accordance with cGMP and QS requirements. 
	7.2	 	☒	 	☐	 	Change
    Control - Inform Biofrontera prior to implementing any changes that may impact US product specifications or will affect the quality
    of finished device or drug product.

 

	8.	Purchasing
  and Material Control System

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	8.1.
    	 	☒	 	☒	 	Establish
    and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements
    including supplier qualification and requalification activities. 
	8.2.
    	 	☒	 	☒	 	Utilize
    components and materials from appropriately approved vendors.
	8.3.
    	 	☒	 	☐	 	Pharma
    will store all materials (components, packaging materials, bulk Product, in-process Product and finished Product) in conditions appropriate
    to maintain material integrity.
	8.4.
    	 	☐	 	☒	 	Biofrontera
    will store all materials (finished product and shipping materials) in conditions appropriate to maintain material integrity.
	8.5.
    	 	☐	 	☒	 	Biofrontera
    will select and approve shipping material for the distribution of products in the US appropriate to maintain material integrity.
	8.6.
    	 	☒	 	☐	 	Label
    and Labeling- Ensure the content and format of Product labels and labeling comply with all applicable regulatory agency requirements.
	8.6.1.
    	 	☒	 	☐	 	Prepare
    and approve master label artwork according to the approved regulatory label. 
	8.6.2.
    	 	☒	 	☐	 	Maintain
    label/labeling control documents for all printed packaging components.
	8.6.3.
    	 	☒	 	☐	 	Inspect
    printed copy against a master label in accordance with standard receiving and inspection procedures.
	8.6.4.
    	 	☒	 	☐	 	Store
    labels/labeling in a limited access area and control throughout manufacturing/packaging/labeling to prevent mix-ups.
	8.6.5.
    	 	☒	 	☐	 	Reconcile
    labeling in accordance with established controls. 
	8.6.6.
    	 	☒	 	☐	 	Segregate
    and quarantine obsolete printed components. Properly destroy excess or obsolete material. 

 

    	Confidential

    	Page 8 of 14

    

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	8.6.7.
    	 	☐	 	☒	 	Ensure
    advertising and promotional materials comply with all applicable regulatory agency requirements via legal, regulatory, compliance
    and quality review.
	8.6.8.
    	 	☒		☐	 	Provide
    current copy of approved label and Prescribing Information to Biofrontera and inform Biofrontera prior to implementing any changes
    to the approved label
	8.6.9.
    	 	☐	 	☒	 	Inform
    Pharma about any new advertising material and provide copies of advertising and promotional material for submission to the Office
    of Prescription Drug Promotion (OPDP) according with the requirements described in 21 CFR 314.81(b)(3)(i) . Also, support Pharma
    as necessary for the preparation of the submission and annotation of the advertising and promotional material.
	8.6.10.
    	 	☒	 	☐	 	Submit
    advertising and promotional material to FDA.
	8.6.11.
    	 	☐	 	☒	 	Ensure
    no advertising and promotional material is distributed prior submission to the FDA.

 

	9.	Laboratory
    Testing and Quality Controls System

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	9.1.
    	 	☒	 	☐	 	Drug
    Product: Identification, sampling, testing and disposition of raw materials shall be performed according to written specifications
    and procedures. Raw materials must be deemed acceptable in accordance with pre-established standards prior to use.
	9.2.
    	 	☒	 	☐	 	Drug
    Product Stability: Determine the minimum number of samples required for full stability testing through expiration date and perform
    stability testing according to approved stability protocol.
	9.3.
    	 	☒	 	☐	 	Drug
    Product: Review, approve and maintain current stability specifications, stability study protocols and stability data
	9.4.
    	 	☒	 	☐	 	Drug
    Product: Assign product expiration dating. 
	9.5.
    	 	☒	 	☐	 	Retain:
                                            Finished Drug Product samples shall be retained for every packaged lot for at least one (1)
                                            year beyond the expiry date of the Product. The quantity retained shall be at least twice
                                            the quantity necessary to perform full testing.

    Visually
    examine retained samples of Drug Product for evidence of deterioration at least annually. Any evidence of deterioration must be documented
    and appropriately investigated.

	9.6.
    	 	☒	 	☐	 	Provide
    paper documents required to determine acceptance of product during inspection, e.g. Certificate of Analysis (CoA)
	9.7.
    	 	☒	 	☐	 	Conduct
    finished goods inspection on the Product prior to release for distribution to Biofrontera. Ensure the finished Product meets the
    established specifications and regulatory requirements.
	9.8.
    	 	☐	 	☒	 	Conduct
    review of CoA and transport documentation prior to release for distribution to customer. Ensure the finished Product meets the established
    specifications and regulatory requirements.
	9.9.
    	 	☒	 	☒	 	All
    testing and inspection must be documented and records retained for a minimum of one (1) year beyond the expiration of the Product.

 

    	Confidential

    	Page 9 of 14

    

 

	10.	Facility
    and Equipment Controls

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	10.1.
    	 	☒	 	☐	 	Manage
    and maintain facilities, work flow and material handling such that components, packaging materials and Product are protected from
    damage, contamination or mix-up during production or storage as long as the product is outside the USA.
	10.2.
    	 	☐	 	☒	 	Manage
    and maintain facilities, work flow and material handling such that Product is protected from damage, contamination or mix-up during
    storage after import in the USA.
	10.3.
    	 	☒	 	☐	 	Ensure
    manufacturing/packaging equipment is appropriately qualified through established validation procedures.
	10.4.
    	 	☒	 	☐	 	Maintain
    a written, validated cleaning/sanitization program to verify all equipment that substantially contacts Product is controlled for
    contamination.
	10.5.
    	 	☒	 	☐	 	Maintain
    and calibrate all equipment and instruments used to produce or test the Product or components thereof at suitable intervals in accordance
    with an established written program. All equipment shall be deemed within calibration at time of use.
	10.6.
    	 	☒	 	☐	 	Ensure
    HVAC systems are adequately qualified.

 

	11.	Production
    and Process Controls

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	11.1.
    	 	☒	 	☐	 	Adopt
    the necessary procedures and/or controls during all phases of manufacturing/packaging to control the quality of the Product and maintain
    sufficient records to comply with regulatory requirements. 
	11.2.
    	 	☒	 	☐	 	Approve
    and document production processes, instructions, and methods that define and control the manner of production. 
	11.3.
    	 	☒	 	☐	 	Monitor
    and control process parameters and device characteristics during production by performing in-process quality control checks in accordance
    with batch record instructions. 
	11.4.
    	 	☒	 	☐	 	Evaluate
    changes to batch records against pre-established requirements.
	11.5.
    	 	☒	 	☐	 	Ensure
    appropriate manufacturing process validation and packaging qualification are performed.

 

	12.	Control
    of Non-Conforming Product, Disposition and Rework

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	12.1.
    	 	☒	 	☒	 	Supplier
    corrective action request (SCAR) - Where a product is identified by Biofrontera as nonconforming, the product shall be returned to
    Pharma for investigation and analysis. Pharma shall cooperate with Biofrontera in working toward closure of the Biofrontera Corrective
    Action Request associated with the Product(s). 
	12.2.
    	 	☒	 	☒	 	Establish
    and maintain procedure for disposition of nonconforming product. The disposition of nonconforming product shall be documented. 
	12.3.
    	 	☒	 	☒	 	Determine
    the procedures for rework, retest, and re-evaluation of Nonconforming product to ensure product meets the specifications. Pharma
    shall document rework activities in the Batch record or equivalent and submit rework report to Biofrontera, upon request. 

 

    	Confidential

    	Page 10 of 14

    

 

	13.	Corrective
    and Preventive Action

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	13.1.
    	 	☒	 	☒	 	Establish
    and maintain procedures for implementing a CAPA system in compliance with the cGMP requirements.
	13.2.
    	 	☒	 	☐	 	Conduct
    appropriate quality investigations upon discovery of non-conformances. Take applicable corrective actions in a manner that will be
    considered timely and effective.
	13.3.
    	 	☐	 	☒	 	Support
    quality investigations, as appropriate.
	13.4.
    	 	☒	 	☐	 	Notify
    Biofrontera in writing within two (2) working days after learning of any actual or potential problems relating to the performance
    of any product manufactured that do not meet specifications. 
	13.5.
    	 	☐	 	☒	 	Notify
    Pharma in writing within two (2) working days after learning of any actual or potential problems relating to the performance of any
    product manufactured that do not meet specifications. 

 

	14.	Handling,
  Storage, Distribution, Installation and Servicing

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	14.1.
    	 	☒	 	☒	 	Handling:
    Establish system in place to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects do not occur during
    handling of the product(s).
	14.2.
    	 	☒	 	☒	 	Storage:
    Control storage area to prevent mix-ups, damage, deterioration, contamination, or other adverse effects pending shipment of the product(s).
	14.3.
    	 	☒	 	☒	 	Distribution:
    Establish system in place to control distribution of product(s) so that only product(s) approved for release are distributed. Ensure
    that no obsolete, rejected, expired or deteriorated products are distributed. Maintain distribution record which includes at least
    – the name and address of initial consignee; the identification and quantity of units shipped; the date shipped and any control
    number used.
	14.4.
    	 	☐	 	☒	 	Biofrontera
    will distribute all materials in US (finished product) in conditions appropriate to maintain material integrity.
	14.5.
    	 	☒	 	☐	 	Provide
    adequate installation instructions for the device.
	14.6.
    	 	☐	 	☒	 	Perform
    installation of the device in accordance with the manufacturer’s instructions.
	14.7.
    	 	☒	 	☐	 	Provide
    instructions and procedures for performing servicing and maintenance for the device.
	14.8.
    	 	☐	 	☒	 	Perform
    servicing and maintenance for the device in the USA.

 

	15.	Shipment

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	15.1.
    	 	☐	 	☒	 	Selection
    and qualification a shipping company.
	15.2.
    	 	☒	 	☐	 	Selection
    and qualification of transport packaging for the medical device.
	15.3.
    	 	☐	 	☒	 	Selection
    and qualification of transport packaging for the drug.
	15.4.
    	 	☐	 	☒	 	Selection,
    qualification and survey of the transport process.

 

    	Confidential

    	Page 11 of 14

    

 

	16.	Records

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	16.1.
    	 	☒	 	☐	 	Maintain
    records of each lot for a period of 1 year after the expiration date of the product. 
	16.2.
    	 	☒	 	☐	 	Records
    related to the product covered under the agreement shall be made available upon request by Biofrontera either by electronic media
    or mail. 
	16.3.
    	 	☐	 	☒	 	Maintain
    records related to drug sample distribution, customer qualification and sunshine act.

 

	17.	Complaints
  and Pharmacovigilance

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	17.1.
    	 	☒	 	☒	 	Maintain
    a Safety Data Exchange Agreement describing the responsibilities related to Pharmacovigilance and Complaint handling in detail
	17.2.
    	 	☐	 	☒	 	Becoming
    aware of product complaints, Biofrontera shall notify Pharma within 24 hours by email or by telephone with written follow up within
    5 business days to perform quality investigation, as appropriate.
	17.3.
    	 	☒	 	☒	 	Maintain
    a written record of all customer complaints that relate to the product whether received orally or in writing. 
	17.4.
    	 	☒	 	☐	 	Prepare
    and submit any MDR and/or ADE as applicable
	17.5.
    	 	☒	 	☐	 	Sole
    authority to correspond with agency with respect to the product complaints. 
	17.6.
    	 	☒	 	☐	 	Establish
    and maintain procedure for Adverse Drug Event and Medical Device Reporting, including PADER required reporting.
	17.7.
    	 	☒	 	☐	 	Responsible
    for complying with all regulatory agency requirements pertaining to the reporting of adverse events and Medical Device Reporting
    (MDR) requirements. 
	17.8.
    	 	☒	 	☒	 	Maintain
    documentation regarding complaints and related for at least one (1) year after expiration date of the Product.

 

18.
Annual Product Reviews and Annual Reports

 

	 	 	Pharma	 	Biofrontera	 	Responsibility
	18.1.
    	 	☒	 	☐	 	APR:
    Perform and maintain written record on an annual basis, evaluating the quality standard of the drug product. 
	18.2.
    	 	☐	 	☒	 	Provide
    data/documentation required for Annual Report within thirty (30) days prior to the anniversary date to Pharma. 

 

    	Confidential

    	Page 12 of 14

    

 

19.
Company Contacts

 

	 	 	Biofrontera
    Pharma GmbH	 	Biofrontera
    Inc.
	Contract
                                            Terms /

    General
    Notices
	 	Hermann
                                            Lübbert

    CEO

    Biofrontera
    Pharma GmbH

    Hemmelrather
    Weg 201

    51377
    Leverkusen

    Germany

    Phone:
    +49 214 8763210

    Fax:
    +49 214 8763290

    email:
    h.luebbert@biofrontera.com
	 	Monica
                                            Tamborini

    COO

    Biofrontera
    Inc.

    201
    Edgewater Drive

    Wakefield,
    MA 01880

    United
    States

    Email:
    m.tamborini@biofrontera.com

    Office:
    781.245.1325

    Fax:
    781.245.1328

    e-mail:
    m.tamborini@biofrontera.com

	 	 	 	 	 
	Quality	 	Wiebke
                                            Meyer-Wendt

    Director
    Quality Management

    Biofrontera
    Pharma GmbH

    Hemmelrather
    Weg 201

    51377
    Leverkusen

    Germany

    Phone:
    +49 214 8763247

    Fax:
    +49 214 8763290

    email:
    w.wendt@biofrontera.com
	 	Darrell
                                            T. Lowman

    Quality
    Assurance Director

    Biofrontera,
    Inc.

    201
    Edgewater Drive

    Wakefield,
    MA 01880

    United
    States

    Phone:
    (781) 245-1325 Ext. 211

    Fax:
    781.245.1328

    e-mail:
    d.lowman@biofrontera.com

	 	 	 	 	 
	Production/
    Logistic	 	Montserrat
                                            Foguet

    Vice
    President Head of Regulatory Affairs and Production

    Biofrontera
    Pharma GmbH

    Hemmelrather
    Weg 201

    51377
    Leverkusen

    Germany

    Phone:
    +49 214 8763231

    Fax:
    +49 214 8763290

    email:
    m.foguet@biofrontera.com
	 	N/A

 

    	Confidential

    	Page 13 of 14

    

 

Attachment
I – Product(s)

 

	Product	 	Regulatory
    Status
	 	 	 
	Ameluz®	 	NDA
	 	 	 
	BF-RhodoLED	 	PMA
    (through NDA)

 

    	Confidential

    	Page 14 of 14

    

 

Attachment
II – Controlled documents to be provided to each other

 

	Document
    Number and Version	 	Topic	 	Owner
	SPE-QC-044,
    version 01	 	Specification
    Ameluz®	 	Pharma
	SPE-QC-036,
    version 02	 	Specification
    BF-RhodoLED	 	Pharma
	Service
    Manual BF-RhodoLED (Version 1.1-US 19.09.2016)	 	Service
    Manual BF-RhodoLED	 	Pharma
	SOP-006
    Service, Rev 001	 	SOP
    Service	 	Biofrontera
	FORM-SOP-006
    Installation Record, Rev 001	 	Installation
    BF-RhodoLED	 	Biofrontera
	SOP-012
    Complaint Program, Rev 001	 	SOP
    Complaint Program	 	Biofrontera
	FORM-SOP-012
    Complaint Form, Rev 001	 	Complaint
    Form	 	Biofrontera

 

    	Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]